Narayana Hrudayalaya Ltd. has submitted to the Exchange, the unaudited Standalone and Consolidated financial results for the quarter and period ended December 31, 2025 approved by the Board at its meeting held on February 13, 2026.
NH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts more than Nifty Smallcap 250 and 0.4 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Narayana Hrudayalaya reported Q3 FY26 standalone revenue of ₹9,687.81 million, up about 12% year-on-year from ₹8,650.43 million. Standalone EBITDA rose 33% to ₹2,206.15 million, but net profit dipped slightly to ₹757.37 million from ₹792.23 million after a ₹452.76 million one-time charge linked to new Labour Codes. On a consolidated basis, revenue jumped 61% to ₹21,511.70 million, largely driven by the UK acquisition of Practice Plus Group Hospitals (closed November 6, 2025), though consolidated net profit fell about 34% to ₹1,280.86 million due to the exceptional item and integration costs. The merger of subsidiary Meridian Medical Research & Hospital Ltd has been approved by shareholders and creditors and is awaiting NCLT approval. The company also incorporated a new wholly owned subsidiary, Narayana Healthcare North Pvt Ltd, to expand in northern India.
Strong consolidated top-line growth is mostly inorganic from the UK deal, while profitability took a hit from the Labour Codes exceptional charge, which may weigh on near-term PAT optics. EBITDA margins improved sharply, which is a positive sign for operating performance, and the UK acquisition could be a long-term growth driver once integrated.